The traditional Chinese medicine Pseudostellaria heterophylla (Tai-Zi-Shen) has been used for millennia, with its therapeutic effects largely attributed to its complex chemical constituents. In recent years, advances in natural product chemistry have highlighted the cyclic peptides derived from this herb as a burgeoning focus in drug discovery, with their unique structural stability and diverse biological activities positioning them as promising candidates. This article delves into a comprehensive review of Pseudostellaria heterophylla cyclic peptide research and explores how advanced chemical synthesis and biotechnologies can bridge the gap from laboratory discovery to industrial application.
Research on cyclic peptides has evolved from the discovery of novel compounds to the elucidation of pharmacological mechanisms. In recent years, with the deep integration of modern pharmacology and medicinal chemistry, the research focus is gradually shifting from basic activity validation to more in-depth druggability assessments. This necessitates a re-evaluation of these natural cyclic peptide molecules in terms of stability, bioavailability, and target selectivity.
Fig.1 Chemical structures of cyclic peptides from P. heterophylla1,2
Pseudostellaria heterophylla, a renowned Qi-tonifying herb in traditional Chinese medicine, has revealed significant potential in its active constituents through modern pharmacological research. Cyclic peptides, particularly heterophyllin A and heterophyllin B, exhibit superior metabolic stability and receptor selectivity compared to linear peptides due to their unique cyclic structures, making them ideal starting points for innovative drug development.
Currently, 19 cyclic peptides have been isolated from Pseudostellaria heterophylla, classified into two main categories: heterophyllin-type and Pseudostellaria heterophylla cyclic peptide-type. These cyclic peptides range from 2 to 10 amino acid residues, with molecular weights spanning 260 to 989 Daltons. This structural diversity provides a material basis for their broad pharmacological activities. The cyclic backbone confers enhanced chemical stability and resistance to enzymatic degradation, resulting in a longer half-life and improved bioavailability in vivo.
These cyclic peptides exhibit significant pharmacological activities, including anti-cancer, antioxidant, anti-inflammatory effects, modulation of gut microbiota, and enhancement of cognitive function. Their mechanisms of action involve key signaling pathways such as PI3K/AKT, AMPK, and MAPK. In terms of anti-tumor activity, heterophyllin B inhibits ovarian cancer cell proliferation by suppressing the NRF2/HO-1 signaling pathway, induces apoptosis in gastric cancer cells by activating the endoplasmic reticulum stress pathway, and blocks tumor immune evasion by binding to the CXCR4 receptor. Regarding anti-inflammatory effects, heterophyllin B significantly inhibits the production of inflammatory factors and reduces reactive oxygen species levels, alleviating spinal cord injury and ulcerative colitis by activating the AMPK pathway. For cognitive enhancement, heterophyllin B can penetrate the blood-brain barrier, promote neuronal outgrowth, regulate monoamine neurotransmitter metabolism, and improve memory function.
The preparation strategy is critical for determining whether Pseudostellaria heterophylla cyclic peptides can achieve large-scale application. The technological evolution—from initial natural extraction, through exploration of biosynthesis, to the current mainstream approach of chemical synthesis—clearly reflects the pursuit of efficient, controllable, and reproducible preparation methods.
Early research on Pseudostellaria heterophylla cyclic peptides relied on direct extraction from the dried root tubers. This involved repeated extraction with organic solvents, followed by separation via column chromatography to obtain the target cyclic peptides. While straightforward, this method suffers from extremely low yields, is time-consuming, and is not scalable. Typically, large quantities of raw material are required to obtain milligram amounts of purified cyclic peptide. To improve efficiency, researchers have explored advanced techniques like high-speed countercurrent chromatography, but the inherent limitations of natural extraction persist.
To address the yield issue, researchers have explored biosynthetic pathways. Two main strategies have been investigated: first, using intein technology to catalyze linear peptide cyclization in vivo within E. coli, successfully synthesizing Pseudostellaria heterophylla cyclic peptide F with yields reaching 2 to 20 mg per liter; second, isolating crude enzymes capable of catalyzing cyclization from Pseudostellaria heterophylla to achieve the enzymatic synthesis of heterophyllin B in vitro. Recent studies have further revealed that the biosynthesis of Pseudostellaria heterophylla cyclic peptides follows the ribosomally synthesized and post-translationally modified peptide pathway, providing a new theoretical foundation for their production. However, these methods are still in the exploratory phase, facing challenges such as unstable yields and complex purification processes.
To meet the demands of in-depth research and potential drug development, chemical synthesis, particularly solid-phase peptide synthesis (SPPS), has become the mainstream method for producing Pseudostellaria heterophylla cyclic peptides. From early methods involving stepwise coupling of dipeptide fragments and cyclization using the p-nitrophenyl ester method, to the widely adopted Fmoc SPPS strategy in recent years, cyclic peptides like PA and HJ have been synthesized efficiently. These studies demonstrate that SPPS can achieve target cyclic peptides with high yields and good reproducibility—for instance, total yields of 76% for PA and 68% for HJ. The advantage of chemical synthesis lies not only in efficiently obtaining natural cyclic peptide products but also in enabling flexible structural modifications and analog synthesis, thereby supporting systematic structure-activity relationship (SAR) studies.
Translating the cutting-edge research findings on Pseudostellaria heterophylla cyclic peptides into tangible drug development projects involves numerous practical industrial challenges. These extend beyond synthesis techniques to encompass process scale-up, quality control, cost management, and regulatory compliance.
The trace amounts obtainable from natural extraction of Pseudostellaria heterophylla cyclic peptides are insufficient for high-throughput screening and preclinical efficacy evaluations; typically, large quantities of medicinal materials yield only milligram quantities of pure product. Early biosynthetic methods are still immature, resulting in unstable yields and difficulty ensuring batch-to-batch consistency and reproducibility. Achieving the transition from milligram to gram, or even kilogram, scale production while controlling costs is a primary challenge for industrial translation.
The lack of comprehensive SAR studies on Pseudostellaria heterophylla cyclic peptides hinders the ability to enhance activity, optimize pharmacokinetic properties, or reduce potential toxicity through systematic structural modification. Current SAR research is still in its infancy, and the structural basis for the activity differences among various cyclic peptides remains unclear. For example, why Pseudostellaria heterophylla cyclic peptide F exhibits the strongest tyrosinase inhibitory activity while cyclic peptide H is relatively weaker requires further investigation.
Transitioning from milligram-scale synthesis in the lab to potential kilogram-scale supply requires a reliable scale-up process. While SPPS performs excellently at small scale, scaling up can introduce challenges such as decreased reaction efficiency and increased purification complexity. Furthermore, as drug candidates, the synthesis process must comply with Good Manufacturing Practice (GMP) standards to ensure quality, safety, and traceability.
Facing the significant challenges in cyclic peptide R&D, Creative Peptides leverages its deep expertise in peptide chemistry to provide a one-stop solution for research and biopharmaceutical partners worldwide. Our team comprises experienced peptide and medicinal chemists who possess an in-depth understanding of the structural characteristics and synthesis challenges associated with cyclic peptides.
| Supply of Cyclic Peptide Standards and Custom Synthesis Services | Milligram-to-Kilogram Scale Production Capabilities for Cyclic Peptides |
Addressing the challenges of preparation efficiency, cost, and structural optimization, we offer comprehensive services ranging from standard supply to custom synthesis:
| To tackle the challenges of process scale-up and regulatory compliance, we possess state-of-the-art facilities and a dedicated team supporting cyclic peptide production from milligram to kilogram scales.
|
| Comprehensive Cyclic Peptide Quality Control | |
At Creative Peptides, we adhere to the highest quality standards for every cyclic peptide project.
|
As innovative molecules rooted in traditional Chinese medicine, cyclic peptides from Pseudostellaria heterophylla have drawn increasing interest from drug developers worldwide. Their unique cyclic structures and broad pharmacological activities make them particularly attractive. As the reviewed literature shows, the field is now moving from discovery toward development—where efficient preparation and thoughtful structural modification will be essential to turning these compounds into real therapies.
Creative Peptides is here to support you on that journey. We offer a one-stop solution covering high-quality cyclic peptide standards, custom synthesis, and scalable production—designed to help you overcome the hurdles in cyclic peptide R&D. Explore our products and services, or reach out to our scientists, and let's work together to advance cyclic peptides toward new therapies.
References
